United Therapeutics Corporation $UTHR Position Boosted by Aviva PLC

Aviva PLC lifted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 1,688.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,122 shares of the biotechnology company’s stock after purchasing an additional 31,270 shares during the period. Aviva PLC owned about 0.07% of United Therapeutics worth $9,518,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CWM LLC boosted its stake in shares of United Therapeutics by 204.3% during the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after acquiring an additional 3,487 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of United Therapeutics during the first quarter valued at $313,000. Allianz Asset Management GmbH boosted its position in shares of United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after purchasing an additional 33,254 shares during the period. LPL Financial LLC increased its stake in United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock worth $7,783,000 after purchasing an additional 11,007 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in United Therapeutics by 77.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after buying an additional 2,655 shares during the period. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $461.54 on Thursday. The company has a market capitalization of $19.87 billion, a P/E ratio of 17.49, a P/E/G ratio of 4.96 and a beta of 0.77. The stock’s 50 day moving average price is $429.43 and its 200 day moving average price is $347.36. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $479.50.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.39 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 456,435 shares of company stock worth $193,342,192 over the last 90 days. Corporate insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on UTHR. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. HC Wainwright increased their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Oppenheimer lifted their price target on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Finally, UBS Group upped their price target on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $503.90.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.